These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 12534060)

  • 1. [Is one antihypertensive agent as good as another?].
    Trenkwalder P
    MMW Fortschr Med; 2002 Nov; 144(45):41-2. PubMed ID: 12534060
    [No Abstract]   [Full Text] [Related]  

  • 2. [LIFE study proves preventive action. With losartan to do even more against stroke].
    Baumgart P
    MMW Fortschr Med; 2003; 145 Suppl 1():7-8. PubMed ID: 12958796
    [No Abstract]   [Full Text] [Related]  

  • 3. [Hypertension plus left ventricular hypertrophy. Prognosis can now be significantly improved].
    Einecke D
    MMW Fortschr Med; 2002 Apr; 144(14):4-5. PubMed ID: 12014276
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study.
    Olsen MH; Wachtell K; Beevers G; Dahlöf B; de Simone G; Devereux RB; de Faire U; Fyhrquist F; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Lyle PA; Nieminen MS; Omvik P; Oparil S; Wedel H
    J Hypertens; 2009 Mar; 27(3):567-74. PubMed ID: 19262226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hypertensive patient with enlarged heart. Caution, risk of atrial fibrillation!].
    MMW Fortschr Med; 2006 May; 148(21):62. PubMed ID: 16796195
    [No Abstract]   [Full Text] [Related]  

  • 6. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
    Okin PM; Wachtell K; Kjeldsen SE; Julius S; Lindholm LH; Dahlöf B; Hille DA; Nieminen MS; Edelman JM; Devereux RB
    Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antihypertensive therapy: risk stratification in diabetes and cardiac diseases].
    Baumgart P
    MMW Fortschr Med; 2006 Mar; 148(11):57, 59-60. PubMed ID: 16612965
    [No Abstract]   [Full Text] [Related]  

  • 8. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Devereux RB; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [AT1 receptor antagonist lorsartan and organ protection. Managing hypertension a different way].
    MMW Fortschr Med; 2006 Mar; 148(13):48-9. PubMed ID: 16642707
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of hypertension in the elderly].
    Hohage H; Gerhardt U; Suwelack BM
    Med Klin (Munich); 2003 Sep; 98(9):511-21. PubMed ID: 14551708
    [No Abstract]   [Full Text] [Related]  

  • 12. [Stress intolerance in diastolic dysfunction. A case for AT1 blocker?].
    MMW Fortschr Med; 2002 Jan; 144(1-2):69. PubMed ID: 11847893
    [No Abstract]   [Full Text] [Related]  

  • 13. [Fewer cases of stroke, atrial fibrillation, diabetes and renal insufficiency. Good treatment of hypertension is more than lowering of blood pressure].
    Baumgart P
    MMW Fortschr Med; 2008 Jan; 150(1-2):52-3. PubMed ID: 18300647
    [No Abstract]   [Full Text] [Related]  

  • 14. The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study.
    Olsen MH; Wachtell K; Dahlöf B; Devereux RB; Ibsen H; Kjeldsen SE; Lindholm LH; Lyle PA; Nieminen MS
    J Hum Hypertens; 2006 Jun; 20(6):460-4. PubMed ID: 16572193
    [No Abstract]   [Full Text] [Related]  

  • 15. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
    Ibsen H; Pedersen OL; Dahlöf B; Kjeldsen SE; Lindholm LH
    Ugeskr Laeger; 2003 Jan; 165(5):456-9. PubMed ID: 12599843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Angiotensin 1-antagonists: primary therapeutic option in arterial hypertension, too].
    Traut
    Dtsch Med Wochenschr; 2003 Jan; 128(4):161; discussion 161-2. PubMed ID: 12589590
    [No Abstract]   [Full Text] [Related]  

  • 17. [Recent intervention studies with antihypertensive drugs and their influence on guidelines].
    Rahn KH
    Med Klin (Munich); 2003 Dec; 98(12):771-5. PubMed ID: 14685679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [In heart diseases, differential hypertension therapy].
    Werner N; Böhm M
    MMW Fortschr Med; 2003 Mar; 145(11):45-8. PubMed ID: 12688196
    [No Abstract]   [Full Text] [Related]  

  • 19. Slower heart rates for healthy hearts: time to redefine tachycardia?
    Gopinathannair R; Sullivan RM; Olshansky B
    Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):321-3. PubMed ID: 19808425
    [No Abstract]   [Full Text] [Related]  

  • 20. [A problem that should be recognized. Greater risk of diabetes with antihypertensive drugs?].
    MMW Fortschr Med; 2004 Dec; 146(51-52):50-1. PubMed ID: 15675247
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.